Analyst: This Penny Stock Could Quadruple

NTGN stock has been sliding in recent weeks

Jun 4, 2019 at 12:20 PM
facebook twitter linkedin


Mizuho initiated coverage on Neon Therapeutics Inc (NASDAQ:NTGN) with a "buy" rating and $21 price target -- a 333% premium to last night's close. The brokerage firm said NTGN's low share price is a result of confusion around neoantigens science, which studies a new cancer therapy.

LifeSci Capital also chimed in, saying the cancer researcher's Phase I neoantigen vaccine study could be "best-in-class," should results of the trial remain consistent. This follows positive data for Neon Therapeutics' peer Genocea Biosciences, which sent its stock gapping higher on Monday.

Analysts are already overwhelmingly bullish on NTGN stock, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $19.13.

Looking closer at the charts, Neon Therapeutics has been in a channel of lower highs and lows since its mid-April peak at $7.51, under pressure from its 20-day moving average. While the shares have recovered since their late-May low at $4.50, they are struggling to break out above their 10-day moving average and year-to-date breakeven mark at $5.03, last seen up 4.3% at $5.06.

ntgn stock daily price chart on june 4

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners